Leading cancer research organizations to host international cancer immunotherapy conference

August 03, 2015

NEW YORK - The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.

Titled "Translating Science into Survival," the meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including: immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.

The full program is available here: http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=54&ItemID=149.

Registration is complimentary for credentialed news media. Members of the media can register using this form: http://www.aacr.org/Documents/15Immuno_RegForm.pdf. Return completed forms to Lauren Riley via email at lauren.riley@aacr.org or via fax at 215-446-7291.

Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley at lauren.riley@aacr.org or 215-446-7155.

Those following on social media can join the conversation on Twitter at #cicon15.
-end-
For more information, contact Julia Gunther at julia.gunther@aacr.org or 267-250-5441, or Jeff Molter at jeff.molter@aacr.org or 267-210-3965.

American Association for Cancer Research

Related Immunotherapy Articles from Brightsurf:

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Taking the itch out of cancer immunotherapy
Researchers from the University of Tsukuba have determined that PD-1 expression on CD8 T cells is the biological pathway that leads to psoriasis-like dermatitis, an unfavorable side effect of cancer immunotherapy with PD-1 inhibitors.

Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

New immunotherapy to beat cancer
Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.

New hydrogels for T-cell growth to be used in cancer immunotherapy
A team with the participation of researchers from the Spanish National Research Council (CSIC) has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A blood test could predict who benefits from immunotherapy
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

Read More: Immunotherapy News and Immunotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.